← Leaderboards
Philip Ross Hardwidge
University Of British Columbia
$7,824,116
Attributed
$7,824,116
Total exposure
20
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $901.5K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,824,116 · 20
By mechanism
P20$1,917,601 · 3
R21$1,785,498 · 5
R56$1,641,135 · 4
R01$1,588,125 · 1
R03$593,303 · 4
R15$213,125 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Pathogen”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$343,790,695
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
- Jeffrey P Krischer · University Of South Florida$130,496,919
- Mark S Klempner · Tufts Medical Center$128,021,180
- Timothy Stedman · American Type Culture Collection$122,230,581
- Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai$99,962,183
Research focus
PathogenProteinsInnovationEscherichia ColiVirulenceCellsType Iii Secretion System PathwayPathway InteractionsNf-Kappa BBacterial ProteinsEscherichia Coli EhecBiochemicalInfectionMolecularEnteric PathogenSalmonellaSignal TransductionAnimal ModelPreventInhibitor/AntagonistMediatingResponseBacterial InfectionsFuture
Grant awards (42)
Molecular and Cellular Biology Core$339,474
P20 · FY2024 · GM · contact PI
Molecular and Cellular Biology Core$341,081
P20 · FY2023 · GM · contact PI
Bacterial Targets of T3SS Effector Proteases$72,498
R03 · FY2023 · AI · contact PI
Molecular and Cellular Biology Core$270,638
P20 · FY2022 · GM · contact PI
T3SS Effector Regulation of Bacterial Metabolism$186,498
R21 · FY2022 · AI · contact PI
Bacterial Targets of T3SS Effector Proteases$72,305
R03 · FY2022 · AI · contact PI
Molecular and Cellular Biology Core$270,638
P20 · FY2021 · GM · contact PI
Developing Bacterial Glycosyltransferase Inhibitors as Anti-Virulence Drugs$614,542
R56 · FY2020 · AI · contact PI
Molecular and Cellular Biology Core$286,978
P20 · FY2020 · GM · contact PI
Using anti-inflammatory bacterial proteins to treat psoriasis$281,593
R56 · FY2018 · AR · contact PI
Functions of Translocated Bacterial Glycosyltransferases$225,000
R21 · FY2018 · AI · contact PI
Bacterial effectors targeting the IKK/NF-kB pathway$375,000
R01 · FY2017 · AI · contact PI
Functions of Translocated Bacterial Glycosyltransferases$187,500
R21 · FY2017 · AI · contact PI
Bacterial effectors targeting the IKK/NF-kB pathway$375,000
R01 · FY2016 · AI · contact PI
Bacterial effectors targeting the IKK/NF-kB pathway$375,000
R01 · FY2015 · AI · contact PI
An enterotoxigenic E. coli protein that antagonizes the NF-kappaB pathway$225,000
R21 · FY2015 · AI · contact PI
Bacterial effectors targeting the IKK/NF-kB pathway$375,000
R01 · FY2014 · AI · contact PI
An enterotoxigenic E. coli protein that antagonizes the NF-kappaB pathway$187,500
R21 · FY2014 · AI · contact PI
Reverse vaccinology of enterotoxigenic E. coli$211,500
R21 · FY2013 · AI · contact PI
Bacterial effectors targeting the IKK/NF-kB pathway$88,125
R01 · FY2013 · AI · contact PI
Bacterial effectors targeting the IKK/NF-kB pathway$375,000
R56 · FY2012 · AI · contact PI
Reverse vaccinology of enterotoxigenic E. coli$187,500
R21 · FY2012 · AI · contact PI
Bacterial effector inhibition of type I interferon$158,452
R21 · FY2012 · AI · contact PI
Delivery of a bacterial inhibitor of NF-kB to colon tumors$66,659
R03 · FY2012 · CA · contact PI
Bacterial effector inhibition of type I interferon$29,048
R21 · FY2012 · AI · contact PI
Delivery of a bacterial inhibitor of NF-kB to colon tumors$8,341
R03 · FY2012 · CA · contact PI
Bacterial effector inhibition of type I interferon$187,500
R21 · FY2011 · AI · contact PI
Delivery of a bacterial inhibitor of NF-kB to colon tumors$75,000
R03 · FY2011 · CA · contact PI
Bacterial effector subversion of host protein trafficking$74,250
R03 · FY2011 · AI · contact PI
Disruption of NF-kB signaling by diarrheagenic Escherichia coli$370,000
R56 · FY2010 · AI · contact PI
MODULATION OF NF-KB SIGNALLING BY E COLI PROTEIN KINASES$269,320
P20 · FY2010 · RR · contact PI
Bacterial effector subversion of host protein trafficking$75,000
R03 · FY2010 · AI · contact PI
Host subversion by E. coli O157:H7 effector proteins$74,250
R03 · FY2010 · AI · contact PI
MODULATION OF NF-KB SIGNALLING BY E COLI PROTEIN KINASES$139,472
P20 · FY2009 · RR · contact PI
Host subversion by E. coli O157:H7 effector proteins$75,000
R03 · FY2009 · AI · contact PI
Emerging virulence factors in diarrheagenic E. coli pathogenesis$213,125
R15 · FY2006 · AI · contact PI
Mechanisms of pathogenic E.coli-host cell interactions$27,864
F32 · FY2005 · AI
Mechanisms of pathogenic E.coli-host cell interactions$6,500
F32 · FY2005 · AI
Mechanisms of pathogenic E.coli-host cell interactions$5,225
F32 · FY2005 · AI
ENTEROPATHOGENIC E. COLI-HOST BINDING PARTNERS$4,132
P41 · FY2004 · RR
Mechanisms of pathogenic E.coli-host cell interactions$36,108
F32 · FY2003 · AI
Mechanisms of pathogenic E.coli-host cell interactions$5,500
F32 · FY2003 · AI